Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback